Engineering Biology: Deploying Automation, AI And Other Engineering Practices To Scale Up Manufacturing

By William Blake, Chief Technology Officer, Human-Based R&D, Danaher

Biopharma leaders are currently facing scalability issues as the demand for advanced therapeutics and new drug modalities continues to grow. More than 2,000 gene therapies and modified cell therapies are currently under development, along with 800-plus non-genetically modified cell therapies, according to the American Society of Gene & Cell Therapy.

The Danaher Life Sciences companies believe the solution is for the biopharmaceutical industry to embrace an “engineering biology” approach. Applying this approach will require developers to adopt automation at every stage, from early discovery through manufacturing, and to lean on artificial intelligence to improve their processes.